Hostname: page-component-78c5997874-s2hrs Total loading time: 0 Render date: 2024-11-20T04:11:53.906Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment-Resistant Bipolar Disorder: A Comparison of Rapid Cyclers and Nonrapid Cyclers

Published online by Cambridge University Press:  07 November 2014

Dong Vo  and
David L. Dunner
Get access Rights & Permissions [Opens in a new window]

Abstract

Background: We investigated clinical factors to determine their relationship to treatment resistance among bipolar patients who had a consultation at a tertiary care facility.

Methods: Patients were separated into two categories: rapid-cycling disorders and nonrapid-cycling disorders. We hypothesized that there would be less usage of lithium carbonate among nonrapid-cycling treatment-resistant patients than among rapid cyclers and also that there would be higher rates of comorbidity seen among nonrapid-cycling than rapid-cycling patients in order to account for these particular patients being treatment resistant.

Findings: Continued recyling and persistent depression characterized rapid cyclers, whereas persistent depression characterized nonrapid cyclers. Less than 30% of patients had adequate lithium treatment and there was no significant difference comparing rapid cyclers with non-rapid cyclers. Rates of comorbidity were also not significantly different between these groups. We also assessed a number of other factors.

Conclusion: Some of these factors were significant, but when a Bonferonni correction was applied, these significant differences were not maintained. The study of treatment resistance among nonrapid-cycling bipolar patients merits further research.

Type
Original Research
Information
CNS Spectrums , Volume 8 , Issue 12: Bipolar Mood Disorder: Recent Developments Across the Spectrum , December 2003 , pp. 948 - 952
Copyright
Copyright © Cambridge University Press 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Dunner, DL, Fieve, RR.The effect of lithium in depressive subtypes. Deniker, P, Radouco-Thomas, C, Villenueve, AI, eds. Vol. 2. Neuropsychopharmacobgy. New York, NY: Pergamon Press, 1978:1109–1115.Google Scholar
2.Stancer, HC, Furlong, FW, Godse, DD.A longitudinal investigation of lithium as a prophylactic agent for recurrent depression. Can Psychiatric Assoc J. 1970;15:29–40.CrossRefGoogle Scholar
3.Dunner, DL, Fieve, RR.Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry. 1974;30:229–233.CrossRefGoogle ScholarPubMed
4.Goodwin, FK, Jamison, KR.Manic Depressive illness. Oxford, England: Oxford University Press; 1990.Google Scholar
5.Nemeroff, CB, Evans, DL, Gyulai, L, et al.Double-blind, placebo-controlled comparison of Imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 2001;158:906–912.CrossRefGoogle ScholarPubMed
6.Fieve, RR, Dunner, DL, Kumbaraci, T, et al.Lithium carbonate prophylaxis of depression in three subtypes of primary affective disorder. Pharmako Psychiatrik Neurophychopharmakolgie. 1976;9:100–107.CrossRefGoogle ScholarPubMed
7.Tondo, L, Baldessarini, RJ, Hennen, J, et al.Lithium treatment and risk of suicidal behavior in bipolar disorder patients. J Clin Psychiatry. 1998;59:405–414.CrossRefGoogle ScholarPubMed
8.Dunner, DL. Diagnostic assessment. Psychiatric Clin N Amer. 1993;16:431–441.CrossRefGoogle ScholarPubMed
9.Hick, SM, Roy-Byrne, PP, Cowley, DS, et al.DSM-III-R personality disorders in a mood and anxiety disorders clinic: prevalence, comorbitity, and clinical correlates. J Affect Disord. 1993;27:71–79.Google Scholar
10.Hamilton, M. The assessment of anxiety by rating. Br J Med Psychol. 1959;32:50–56.CrossRefGoogle ScholarPubMed
11.Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.CrossRefGoogle ScholarPubMed
12.Montgomery, SA, Asberg, M.A new depression rating scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–389.CrossRefGoogle ScholarPubMed
13.Rosenthal, NE, Sack, DA, Gillin, JC, et al.Seasonal affective disorder: a description of the syndrome and preliminary findings with light therapy. Arch Gen Psychiatry. 1984;41:72–80.CrossRefGoogle ScholarPubMed
14.Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.Google Scholar
15.Bowden, CL, Brugger, AM, Swann, AC, et al.Efficacy of divalproex vs lithium in the treatment of mania. The Depakote Mania Study Group. JAMA. 1994;271:918–924.Google ScholarPubMed
16.Calabrese, JR, Bowden, CL, Sachs, GS, et al.A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry. 1999;60:79–88.CrossRefGoogle ScholarPubMed
17.Practice guideline for the treatment of patients with bipolar disorder (Revision). Am J Psychiatry. 2002;159:1–50.Google Scholar
18.Baker, RW, Vieta, E, Ketter, TA, et al.Olanzapine and olanzapine-fluoxetine combination (OFC) in the treatment of bipolar depression. Paper presented: Annual Meeting of the American College of Neuropsychopharmacology; 12 8-12, 2002; San Juan, PR.Google Scholar
19.Tohen, M, Marneros, A, Bowden, C, et al.Olanzapine versus lithium in relapse prevention: a randomized double blind controlled 12-month clinical trial. Paper presented at: Annual Meeting of the American College of Neuropsychopharmacology; 12 8–12, 2002; San Juan PR.Google Scholar
20.Himmelhoch, JM, Thase, ME, Mallinger, AG, et al.Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry. 1991;148:910–916.Google ScholarPubMed
21.Cohn, JB, Collins, G, Ashbrook, E, et al.A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder, Int Clin Psychopharmacol. 1989;4:313–322.CrossRefGoogle ScholarPubMed
22.Sachs, GS, Later, B, Stoll, AL, et al.A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry. 1994;55:391–393.Google ScholarPubMed
23.Peet, M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry. 1994;164:549–550.CrossRefGoogle ScholarPubMed
24.Amsterdam, J. Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode. J Clin Psychopharmacol. 1998;18:414–417.CrossRefGoogle ScholarPubMed
25.Bowden, CL, Calabrese, JR, McElroy, SL, et al.A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry. 2000;57:481–489.CrossRefGoogle ScholarPubMed
26.Dunner, DL, Stallone, F, Fieve, RR.Lithium carbonate and affective disorders. V. A double-blind study of prophylaxis of depression in bipolar illness. Arch Gen Psychiatry. 1976;33:117–120.CrossRefGoogle Scholar
27.Dunner, DL, Stallone, F, Fieve, RR.Prophylaxis with lithium carbonate: an update. Arch Gen Psychiatry. 1982;39;1344–1345.Google ScholarPubMed
28.Cole, AJ, Scott, J, Ferrier, IN.Patterns of treatment resistance in bipolar affective disorder. Acta Psychiatrica Scand. 1993;88:121–123.CrossRefGoogle ScholarPubMed
29.Sachs, GS. Treatment-resistant bipolar depression. Psychiatr Clin N Am. 1996;19:215–236.CrossRefGoogle ScholarPubMed
30.Nelsen, MR, Dunner, DL.Clinic and differential diagnostic aspects of treatment resistant depression. J Psych Research. 1995;29:43–50.CrossRefGoogle ScholarPubMed